#BioAtla - Twitter Hashtag

11 months ago

BioAtla: Median Overall Survival of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC $BCAB, #BioAtla https://t.co/5HGcih4QMt

0

3

0

1

2K

Crwe World @CrweWorld

almost 2 years ago

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody $BCAB, $CNTX, #BioAtla, #ContextTherapeutics, #ContextTx https://t.co/E2nBfYSDqr

0

3

0

390

Rare Diseases @CheckOrphan

about 2 years ago

BioAtla Granted Fast Track Designation for Ozuriftamab Vedotin in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) - #BioAtla #Carcinoma #HNSCC #Cancer #RareDiseases #OrphanDrugs

CheckOrphan's tweet photo. BioAtla Granted Fast Track Designation for Ozuriftamab Vedotin in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) - #BioAtla #Carcinoma #HNSCC #Cancer #RareDiseases #OrphanDrugs https://t.co/Z47VVWXQbC

0

2

0

312

Tickeron

@Tickeron

almost 4 years ago

$BCAB enters a Downtrend because Momentum Indicator dropped below the 0 level on October 11, 2022. View odds for this and other indicators: https://t.co/7MykoXUtbL #BioAtla #stockmarket #stock

Tickeron's tweet photo. $BCAB enters a Downtrend because Momentum Indicator dropped below the 0 level on October 11, 2022. View odds for this and other indicators: https://t.co/7MykoXUtbL #BioAtla #stockmarket #stock https://t.co/dk6L1YXM4K

0

1

0

SEC.report @EdgarInsider

over 4 years ago

FORM 8-K [Press/News Current Report] recently SEC filed. $BCAB #BioAtla, Inc. https://t.co/osYO2IUlQM

0

1

0

Mass General Brigham Innovation @MGBInnovation

over 5 years ago

"CAR-T | Solid Tumors Success | When?" panel at #WMIF2021. Panelists from @NovartisScience, @Mustang_Bio, @AllogeneTx, and #BioAtla; moderated by Oladapo Yeku, MD PhD, Clinical Assistant in Medicine @MGHCancerCenter. #CarT #CarTCell #celltherapy

MGBInnovation's tweet photo. "CAR-T | Solid Tumors Success | When?" panel at #WMIF2021.

Panelists from @NovartisScience, @Mustang_Bio, @AllogeneTx, and #BioAtla; moderated by Oladapo Yeku, MD PhD, Clinical Assistant in Medicine @MGHCancerCenter. #CarT #CarTCell #celltherapy https://t.co/2Uto7K2fPK

0

4

2

0

Capitalise.ai - Code-free trading automation @Capitalise_ai

over 5 years ago

This poll was particularly interesting🧐 59.1% of you said #ContextLogic- WISH will close up by the highest percentage. However, #BioAtla closed the highest (72.33%)! Seize every trading opportunity with #CapitaliseAI >>

Capitalise_ai's tweet photo. This poll was particularly interesting🧐
59.1% of you said #ContextLogic- WISH will close up by the highest percentage.

However, #BioAtla closed the highest (72.33%)!

Seize every trading opportunity with #CapitaliseAI >>

0

3

0

IPO MARKET WATCH @watch_ipo

over 5 years ago

🟢 IPO #BioAtla $BCAB Stock Going Public 12/16/2020 https://t.co/yeEsUE2ZkI 🟢 SPAC $QELL Acquisition Corp. & EV #Proterra Merger Rumours https://t.co/mt469cKaa2 🟢 IPO #Scopus $SCPS Going Public 12/16/2020 https://t.co/8b8fREaxth

0

1

0

Capitalise.ai - Code-free trading automation @Capitalise_ai

over 5 years ago

#NASDAQ IPOs Wed 16th Dec: #BioAtla #ContextLogic & #UpstartHoldings Which will close up by the highest percentage? Research: BCAB: https://t.co/0mzEsa8G9E WISH: https://t.co/IXfuvysgev UPST: https://t.co/v3MYI1p9VN Trade Like a Machine at #CapitaliseAI https://t.co/ItapRR5jgs

0

4

0